ACST Acasti Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACST

Price (delayed)

$2.87

Market cap

$26.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.08

Enterprise value

$8.46M

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid ...

Highlights
The debt has shrunk by 95% YoY and by 48% QoQ
The EPS has dropped by 150% year-on-year but it rose by 6% since the previous quarter
Acasti Pharma's net income has plunged by 125% YoY but it has increased by 3.7% from the previous quarter
The company's equity fell by 33% YoY and by 3.1% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acastipharma.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of ACST
Market
Shares outstanding
9.4M
Market cap
$26.98M
Enterprise value
$8.46M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$48.9M
EBITDA
-$48.89M
Free cash flow
-$13.47M
Per share
EPS
-$5.08
Free cash flow per share
-$1.17
Book value per share
$6.88
Revenue per share
$0
TBVPS
$2.34
Balance sheet
Total assets
$76.19M
Total liabilities
$11.51M
Debt
$24,000
Equity
$64.68M
Working capital
$25.11M
Liquidity
Debt to equity
0
Current ratio
15.19
Quick ratio
14.73
Net debt/EBITDA
0.38
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.6%
Return on equity
-58.9%
Return on invested capital
-2,993.8%
Return on capital employed
-65.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACST stock price

How has the Acasti Pharma stock price performed over time
Intraday
-1.03%
1 week
-14.84%
1 month
-15.59%
1 year
-82.86%
YTD
-0.69%
QTD
-16.2%

Financial performance

How have Acasti Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.66M
Net income
-$38.77M
Gross margin
N/A
Net margin
N/A
ACST's operating income has dropped by 158% year-on-year but it is up by 2.5% since the previous quarter
Acasti Pharma's net income has plunged by 125% YoY but it has increased by 3.7% from the previous quarter

Growth

What is Acasti Pharma's growth rate over time

Valuation

What is Acasti Pharma stock price valuation
P/E
N/A
P/B
0.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 150% year-on-year but it rose by 6% since the previous quarter
The stock's P/B is 86% below its 5-year quarterly average of 3.0 but 5% above its last 4 quarters average of 0.4
The company's equity fell by 33% YoY and by 3.1% QoQ

Efficiency

How efficient is Acasti Pharma business performance
Acasti Pharma's ROIC has increased by 29% from the previous quarter
The ROA has contracted by 9% from the previous quarter
The ROE has contracted by 8% from the previous quarter

Dividends

What is ACST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACST.

Financial health

How did Acasti Pharma financials performed over time
Acasti Pharma's quick ratio has surged by 58% YoY but it has decreased by 26% QoQ
The company's current ratio has surged by 56% YoY but it fell by 27% QoQ
The debt is 100% lower than the equity
Acasti Pharma's debt to equity has shrunk by 100% YoY
The debt has shrunk by 95% YoY and by 48% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.